How close are we to personalized mitotane dosing in the treatment of adrenocortical carcinoma? State of the art and future perspectives

R.V. Steenaard, M.H.T. Ettaieb, T.M.A. Kerkhofs, H.R. Haak*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Original languageEnglish
Pages (from-to)677-683
Number of pages7
JournalExpert Opinion on Drug Metabolism & Toxicology
Volume17
Issue number6
DOIs
Publication statusPublished - 3 Jun 2021

Keywords

  • Adrenocortical carcinoma
  • mitotane
  • personalized treatment
  • pharmacokinetics
  • pharmacogenetics
  • CYTOTOXIC ACTIVITY
  • ER STRESS
  • IN-VITRO
  • PLASMA
  • CANCER
  • ACTIVATION
  • O,P'-DDD
  • COMBINATION
  • METABOLITES
  • MODULATION

Cite this